| INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
Arcalyst vs Kineret
Side-by-side clinical, coverage, and cost comparison for interleukin 1 receptor antagonist deficiency.Deep comparison between: Arcalyst vs Kineret with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKineret has a higher rate of injection site reactions vs Arcalyst based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kineret but not Arcalyst, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Arcalyst
Kineret
At A Glance
SC injection
Once weekly
IL-1 blocker
SC injection
Daily
IL-1 receptor antagonist
Indications
- Cryopyrin-Associated Periodic Syndromes
- Familial cold urticaria
- Muckle-Wells Syndrome
- INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
- Recurrent pericarditis
- Rheumatoid Arthritis
- Chronic Infantile Neurological, Cutaneous, and Articular Syndrome
- INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
Dosing
Cryopyrin-Associated Periodic Syndromes, Familial cold urticaria, Muckle-Wells Syndrome, Recurrent pericarditis Adults: 320 mg loading dose (two 160 mg SC injections on the same day), then 160 mg SC once weekly; pediatric 12-17 years: 4.4 mg/kg (max 320 mg) loading dose (one or two SC injections), then 2.2 mg/kg (max 160 mg) SC once weekly.
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY Adults: 320 mg SC once weekly as two injections (max 2 mL each) on the same day at two different sites; pediatric patients >=10 kg: 4.4 mg/kg (max 320 mg) SC once weekly as one or two injections (max 2 mL each).
Rheumatoid Arthritis 100 mg/day SC; administer every other day in severe renal insufficiency or ESRD (creatinine clearance <30 mL/min).
Chronic Infantile Neurological, Cutaneous, and Articular Syndrome Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; once daily or split into twice daily; administer every other day in severe renal insufficiency or ESRD.
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; administer every other day in severe renal insufficiency or ESRD.
Contraindications
—
- Known hypersensitivity to E. coli-derived proteins, anakinra, or any components of the product
Adverse Reactions
Most common Injection-site reactions, upper respiratory tract infection, sinusitis, cough, hypoesthesia
Serious Serious infections, risk of malignancy, hypersensitivity reactions, lipid profile changes, neutropenia
Most common (>=5%) Injection site reaction, worsening of RA, upper respiratory tract infections, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain
Serious Serious infections (cellulitis, pneumonia, bone and joint infections), neutropenia (particularly in combination with TNF blocking agents), lymphoma, other malignancies
Postmarketing Transaminase elevations, non-infectious hepatitis, thrombocytopenia (including severe), DRESS, injection site amyloid deposits
Pharmacology
Rilonacept is an IL-1alpha and IL-1beta cytokine trap that acts as a soluble decoy receptor, blocking IL-1 signaling by preventing IL-1alpha and IL-1beta from interacting with cell surface receptors; it also binds IL-1 receptor antagonist (IL-1ra).
IL-1 receptor antagonist; anakinra is a recombinant human IL-1Ra that competitively inhibits IL-1alpha and IL-1beta binding to the interleukin-1 type I receptor (IL-1RI), blocking downstream inflammatory and immunological responses including cartilage degradation and bone resorption.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Arcalyst
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
Kineret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Arcalyst
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (2/8) · Qty limit (0/8)
Kineret
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Humana
Arcalyst
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Kineret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Kiniksa Pharmaceuticals Copay Assistance Program: ArcalystCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ArcalystView full Arcalyst profile
KineretView full Kineret profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.